Industry Analysis
Over the last few years, various monoclonal antibodies targeting immunological checkpoints such as CTLA-4, PD-1, and PD-L1 have been approved, each with its own mode of action. Manufacturers are concentrating their efforts on creating medications from many classifications to treat various disorders, from cancer to rare diseases.
Monoclonal antibodies combined...
0 Commentarios
0 Acciones
2125 Views
0 Vista previa